Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm, Open-label, and Multicenter Phase Ⅱ Study Designed to Evaluate the Efficacy and Safety of Rulonilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

NCT05741021 is registered in ClinicalTrials.gov with Shandong New Time Pharmaceutical Co., LTD as lead sponsor.

NCT NCT05741021
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05741021 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm, Open-label, and Multicenter Phase Ⅱ Study Designed to Evaluate the Efficacy and Safety of Rulonilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
Lead sponsor
Shandong New Time Pharmaceutical Co., LTD
Phase
Phase 2
Overall status
Unknown status
Start date
March 1, 2023
Completion date
October 25, 2024
Enrollment
84 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer, nsclc, pd-1